Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects

Autor: Goyal, Navin, Skrdla, Pete, Schroyer, Rosemary, Kumar, Subramanya, Fernando, Disala, Oughton, Anna, Norton, Nicola, Sprecher, Dennis L, Cheriyan, Joseph

INTRODUCTION AND OBJECTIVE: Pulmonary capillary endothelial transient receptor potential vanilloid 4 (TRPV4) channel plays a critical role in mediating the development of cardiogenic pulmonary edema. GSK2798745 is a first-in-class, highly potent, sel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e408f99acec337f3291aa07db77047a

Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects.

Autor: Goyal N; GlaxoSmithKline, UP4300 East, 1250 S College Road, Collegeville, PA, 19426, USA. navinkumar.s.goyal@gsk.com., Skrdla P; GlaxoSmithKline, UP4300 East, 1250 S College Road, Collegeville, PA, 19426, USA., Schroyer R; GlaxoSmithKline, UP4300 East, 1250 S College Road, Collegeville, PA, 19426, USA., Kumar S; GlaxoSmithKline Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, UK., Fernando D; GlaxoSmithKline Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, UK., Oughton A; GlaxoSmithKline, UP4300 East, 1250 S College Road, Collegeville, PA, 19426, USA., Norton N; GlaxoSmithKline Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, UK., Sprecher DL; GlaxoSmithKline, UP4300 East, 1250 S College Road, Collegeville, PA, 19426, USA., Cheriyan J; GlaxoSmithKline Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Publikováno v: American journal of cardiovascular drugs : drugs, devices, and other interventions [Am J Cardiovasc Drugs] 2019 Jun; Vol. 19 (3), pp. 335-342.